Harvard Researchers Develop CRISPR Method to Study How Gene Mutations Shape Developing Organs
By
Renate Hellmiss
Summary
Researchers from Harvard's MCB Professor Sharad Ramanathan lab have developed a new CRISPR-based method to study how genetic mutations affect the coordinated movements of thousands of cells that shape developing organs. Published in eLife, this approach addresses a longstanding challenge in developmental biology — understanding how single gene mutations alter organ shape at the tissue level, not just in individual cells.
Source
Key quotes
· 3 pulledUnderstanding how a single genetic mutation can alter the shape of a developing organ has long posed a challenge for developmental biologists.
While researchers can readily study the effects of gene mutations on individual cells, uncovering how those mutations influence the coordinated movements of thousands of cells that sculpt tissues and organs has been much more difficult.
Now, researchers from the lab of MCB Professor Sharad Ramanathan have developed a new approach that makes those questions far easier to investigate.
You might also wanna read
Study unveils new genetic screen for understanding human development

New CRISPR Technique Selectively Destroys Cancer Cells with Common Mutation
Researchers at UC Berkeley, UCSF, and Gladstone Institutes have developed a novel CRISPR-based technique called "RNA-Triggered Chromatin Shr
innovativegenomics.org·25d agoCrispr-Edited Pancreatic Cells Successfully Transplanted in Type 1 Diabetes Patient for the First Time
For the first time, researchers have successfully implanted Crispr-edited pancreatic cells into a patient with type 1 diabetes. The gene-edi
CRISPR's Limitations in Mitochondrial DNA Editing and Emerging Alternatives
The article discusses the limitations of CRISPR gene editing technology in accessing mitochondrial DNA (mtDNA) and the resulting challenges

Small-molecule switches put therapeutic CRISPR editing under on-demand control in living tissues


Comments
Sign in to join the conversation.
No comments yet. Be the first.